Search Result

Results for "

CYP2C9 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apoptosis (4) Autophagy (12) Bacterial (3) Calcium Channel (3) Cholinesterase (ChE) (1) COX (5) Cytochrome P450 (53) Dihydrofolate reductase (DHFR) (1) Drug Metabolite (1) EGFR (1) Endogenous Metabolite (8) FGFR (1) Fungal (2) Glucocorticoid Receptor (2) HBV (1) HCV Protease (2) HIV (2) Indoleamine 2,3-Dioxygenase (IDO) (1) Insecticide (1) Isotope-Labeled Compounds (6) mGluR (1) Monocarboxylate Transporter (1) Necroptosis (2) NF-κB (2) Parasite (1) Potassium Channel (4) PPAR (10) Pyruvate Kinase (1) Reference Standards (10) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) ROCK (1) Sodium Channel (2) URAT1 (2) Urease (1) Virus Protease (2) VKOR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (19) Cardiovascular Disease (19) Infection (12) Inflammation/Immunology (22) Metabolic Disease (8) Neurological Disease (9)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00048

Bucolome Paramidin; Paramidine	Cytochrome P450	Inflammation/Immunology
Bucolome is a *CYP2C9* inhibitor, used as an uricosuric agent or anti-inflammatory agent.

HY-N1201

Apigenin Maximum Cited Publications 32 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893

Tetrahydrocurcumin 2 Publications Verification HZIV 81-2	Cytochrome P450 Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-N1201R

Apigenin (Standard) Maximum Cited Publications 32 Publications Verification 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Reference Standards Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-119996

AR-C141990	Monocarboxylate Transporter Cytochrome P450	Inflammation/Immunology
AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a K_i of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC₅₀ values of 16 μM .

HY-151251

CYP2C9/CYP2C19-IN-1	Cytochrome P450 Virus Protease	Infection
CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-164031

Cloperidone	Cytochrome P450	Cancer
Cloperidone is an inhibitor for cytochrome P450 2C9 (CYP2C9) with an IC₅₀ of 17.7 μM. Cloperidone exhibits cytotoxicity on HepG2 cells expressing CYP2C9 (60% survival rate at 10 μM) .

HY-167872

Bifeprofen	Cytochrome P450	Others
Bifeprofen, a cytochrome P450 2C9 (CYP2C9) inhibitor, exhibits dose-dependent inhibition (75 μM, 50%) .

HY-N1201S1

Apigenin-13C	Isotope-Labeled Compounds Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology
Apigenin- ¹³C is the ¹³C-abeled Apigenin (HY-N1201). Apigenin is a competitive CYP2C9 inhibitor with a K_i of 2 μM .

HY-N1201S

Apigenin-d5	Isotope-Labeled Compounds Endogenous Metabolite Autophagy Cytochrome P450	Inflammation/Immunology
Apigenin-d5 is a deuterated labeled Apigenin . Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0688

Linderane	Cytochrome P450	Inflammation/Immunology
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N0893R

Tetrahydrocurcumin (Standard) HZIV 81-2 (Standard)	Reference Standards Cytochrome P450 Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Tetrahydrocurcumin (Standard) is the analytical standard of Tetrahydrocurcumin. This product is intended for research and analytical applications. Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.

HY-177070

Angexostat	Xanthine Oxidase	Inflammation/Immunology
Angexostat (Compound 2) is an inhibitor of xanthine oxidase. Angexostat exhibits high permeability. Angexostat inhibits CYP2C9 with an IC₅₀ of 18.1 μM. Angexostat can be studied in research for xanthine oxidase-related diseases such as hyperuricemia and gout .

HY-134999

10-Hydroxywarfarin	Drug Metabolite Cytochrome P450 VKOR	Metabolic Disease
10-Hydroxywarfarin, a metabolite of (R)-(+)-Warfarin (HY-W015998 ), is a *CYP2C9* and vitamin K epoxide reductase complex 1 (VKOR) inhibitor with IC₅₀s of 1.6 µM and 80 ng/mL, respectively .

HY-N0688R

Linderane (Standard)	Reference Standards Cytochrome P450	Inflammation/Immunology
Linderane (Standard) is the analytical standard of Linderane. This product is intended for research and analytical applications. Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-B0258

Gemfibrozil 2 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-N8382

Chalepensin	Cytochrome P450	Neurological Disease
Chalepensin, a furanocoumarin, is a competitive CYP2A6 inhibitor. Chalepensin also inhibits human CYP1A1, CYP1A2, CYP2A13, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 to different extents .

HY-153970

URAT1 inhibitor 7	URAT1	Inflammation/Immunology
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC₅₀ of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits *CYP2C9, with an IC₅₀* of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .

HY-128859

EMT inhibitor-2	Cytochrome P450	Metabolic Disease
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC₅₀s of 49.72 and 5.54 μM, respectively .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-151253

CYP2C1/CYP2C19-IN-2	Cytochrome P450 Virus Protease	Infection
CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .

HY-131495

(S)-6-O-Desmethylnaproxen (S)-6-Desmethyl Naproxen	COX	Inflammation/Immunology
(S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.

HY-B0258R

Gemfibrozil (Standard) 2 Publications Verification CI-719 (Standard)	Reference Standards PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-117925

Personalised postprandial-targeting	HBV	Others
Personalised postprandial-targeting is a way to modulate water-heme interactions with activity against low-spin P450 complexes. Personalised postprandial-targeting is able to maintain the axial water ligands of CYP2C9 even in the presence of inhibitors. Personalised postprandial-targeting also allows the hydrogen atoms of the axial water ligands to be observed by EPR spectroscopy, providing insights into the enzyme active site .

HY-175169

Urease-IN-21	Bacterial Urease	Infection
Urease-IN-21 (Compound 11b) is a Urease inhibitor with an IC₅₀ of 0.12  μM. Urease-IN-21 has potent antibacterial activity against helicobacter pylori (H. pylori) and inhibitor activity against P450 enzyme (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 can be used for H. pylori infection research .

HY-114759

MS-PPOH	Cytochrome P450	Neurological Disease Metabolic Disease Cancer
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and *CYP2C9* with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .

HY-17356

Fenofibrate 15+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-114415

AWZ1066S	Parasite	Infection
AWZ1066S is a highly potent, specific and orally active anti-Wolbachia agent with EC₅₀ value of 121 nM. AWZ1066S also is a weak CYP2C9 inhibitor and a weak CYP3A4 inducer with IC₅₀ values of 9.7 μM and 37 uM, respectively. AWZ1066S can be used for the research of tropical diseases such as Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) .

HY-100386

Ticlopidine 1 Publications Verification PCR 5332	Cytochrome P450	Cardiovascular Disease
Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.

HY-N0920

Dihydrokavain 7,8-Dihydrokawain; 7,8-Dihydrokavain; Marindinin	COX Cytochrome P450	Neurological Disease Inflammation/Immunology
Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects .

HY-144652

IDO1-IN-19	Indoleamine 2,3-Dioxygenase (IDO) Calcium Channel Sodium Channel Potassium Channel Cytochrome P450	Cardiovascular Disease Cancer
IDO1-IN-19 (Compound 17) is an orally active IDO1 inhibitor with an IC₅₀ of *CYP2C9* of 8.64 μM. IDO1-IN-19 also acts funciton on cardiac channels, with IC₅₀s of 12 μM (IKr), 40 μM (INa), 8.3 μM (ICa), respectively. IDO1-IN-19 has the potential to study cancer diseases .

HY-147807

HIV-1 inhibitor-40	HIV Cytochrome P450	Infection
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC₅₀ of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC₅₀ values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .

HY-B0258S1

Gemfibrozil-d6-1 CI-719-d₆-1	Cytochrome P450 PPAR Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-169119

Antifungal agent 114	Cytochrome P450 Fungal	Infection
Antifungal agent 114 (Compound 19g) is an inhibitor for Cytochrome P450, that inhibits CYP1A2, CYP2C9, CYP2C19 CYP2D6 and CYP3A4 at 10 μM. Antifungal agent 114 exhibits antifungal activity against Cryptococcus neoformans, Candida and Aspergillus, with MIC <0.0625 μg/mL. Antifungal agent 114 exhibits good metabolic stability in human liver microsomes with a half-time of 107 minutes .

HY-17356S2

Fenofibrate-13C6	Isotope-Labeled Compounds Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-17356S1

Fenofibrate-d4	PPAR Autophagy Cytochrome P450	Cardiovascular Disease
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-W013268

(S)-(+)-N-3-Benzylnirvanol (+)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a K_i of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .

HY-17356R

Fenofibrate (Standard) 15+ Cited Publications	Reference Standards PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-12946

BI 653048	Glucocorticoid Receptor Cytochrome P450 HCV Protease	Infection Inflammation/Immunology
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC₅₀ value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC₅₀>30 μM) . BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .

HY-159143

BChE-IN-33	Cholinesterase (ChE) Cytochrome P450	Neurological Disease
BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, *CYP2C9, CYP2D6*. BChE-IN-33 shows potent antioxidant activity with IC₅₀ values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research .

HY-172897

EGFR/DHFR-IN-2	EGFR Dihydrofolate reductase (DHFR) Apoptosis Cytochrome P450	Cancer
EGFR/DHFR-IN-2 (9b) is a dual h-DHFR/EGFR ^TK inhibitor, with IC₅₀ values of 0.192 μM and 0.109 μM for h-DHFR and EGFR, respectively. EGFR/DHFR-IN-2 (9b) halts the cell cycle at the G1/S phase and induces apoptosis. EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. EGFR/DHFR-IN-2 (9b) can be used in the cancer research .

HY-N0920R

Dihydrokavain (Standard) 7,8-Dihydrokawain (Standard); 7,8-Dihydrokavain (Standard); Marindinin (Standard)	Reference Standards COX Cytochrome P450	Neurological Disease Inflammation/Immunology
Dihydrokavain (Standard) (7,8-Dihydrokawain (Standard)) is the analytical standard of Dihydrokavain (HY-N0920). This product is intended for research and analytical applications. Dihydrokavain is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects.

HY-141547

Nav1.7-IN-8	Sodium Channel Cytochrome P450	Inflammation/Immunology
Nav1.7-IN-8 is a potent blockage of NaV1.7 with high selectivity for the inhibition of NaV1.7 over the subtypes hNaV1.1 and hNaV1.5. Nav1.7-IN-8 inhibits *CYP2C9* and CYP3A4 with an IC₅₀ of 0.17 μM and 0.077 μM, respectively. Nav1.7-IN-8 displays significant analgesic effects in rodent models of acute and inflammatory pain .

HY-131495R

(S)-6-O-Desmethylnaproxen (Standard) (S)-6-Desmethyl Naproxen (Standard)	Cytochrome P450 Reference Standards	Inflammation/Immunology
(S)-6-O-Desmethylnaproxen (Standard) is the analytical standard of (S)-6-O-Desmethylnaproxen. This product is intended for research and analytical applications. (S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.

HY-W587878

Thujopsene	Cytochrome P450 Pyruvate Kinase Fungal Apoptosis Insecticide	Infection Cancer
Thujopsene is the inhibitor for cytochrome P450, that inhibits CYP2B6, CYP3A4, CYP2C19, CYP2C8, *CYP2C9* with IC₅₀s of 1.3, 12.6, 13.6, 29.8, and 44.9 μM, respectively. Thujopsene binds to PKM2, inhibits the metabolism pathway of cancer cell, induces apoptosis in MKN45, thereby exhibiting antitumor efficacy. Thujopsene exhibits anti-termite and antifungal activities through autoxidation .

HY-148597

FGFR-IN-10	FGFR Cytochrome P450	Cancer
FGFR-IN-10 is an orally active inhibitor of FGFR and Cytochrome P450 (CYPs). FGFR-IN-10 inhibits wide type and V564F mutant FGFR2 with IC₅₀s of 104.1 nM and 43.6 nM, respectively. FGFR-IN-10 also inhibits CYPs with IC₅₀s of 3.33 μM (CYP2C9), 18.75 μM (CYP2C19), 4.34 μM (CYP2CD6), and 0.69 μM (CYP3A4), respectively .

HY-100386S

Ticlopidine-d4 PCR 5332-d₄	Isotope-Labeled Compounds Cytochrome P450	Cardiovascular Disease
Ticlopidine-d₄ is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-100386R

Ticlopidine (Standard) PCR 5332 (Standard)	Reference Standards Cytochrome P450	Cardiovascular Disease
Ticlopidine (Standard) is the analytical standard of Ticlopidine. This product is intended for research and analytical applications. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1201

Apigenin Maximum Cited Publications 32 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Structural Classification Classification of Application Fields Flavones Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Sunscreen Phenols Polyphenols Cosmetic Research Umbelliferae Baccharis sarothroides A.Gray Disease Research Fields Cancer	Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893

Tetrahydrocurcumin 2 Publications Verification HZIV 81-2	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Endogenous metabolite Microorganisms Phenols Polyphenols Curcuma longa Inflammation/Immunology Disease Research Fields Zingiberaceae Cancer	Cytochrome P450 Autophagy Endogenous Metabolite
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-N1201R

Apigenin (Standard) Maximum Cited Publications 32 Publications Verification 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Sunscreen Phenols Cosmetic Research Umbelliferae Baccharis sarothroides A.Gray Disease Research Fields Cancer	Reference Standards Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0688

Linderane	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Plants Lauraceae Lindera aggregata (Sims) Kosterm. Inflammation/Immunology Disease Research Fields	Cytochrome P450
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N0893R

Tetrahydrocurcumin (Standard) HZIV 81-2 (Standard)	Structural Classification Microorganisms Source classification Phenols Polyphenols Plants Curcuma longa Endogenous metabolite Zingiberaceae	Reference Standards Cytochrome P450 Autophagy Endogenous Metabolite
Tetrahydrocurcumin (Standard) is the analytical standard of Tetrahydrocurcumin. This product is intended for research and analytical applications. Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.

HY-N8382

Chalepensin	Structural Classification Natural Products Haloxylon ammodendron (C. A. Mey.) Bunge Source classification Amaranthaceae Plants	Cytochrome P450
Chalepensin, a furanocoumarin, is a competitive CYP2A6 inhibitor. Chalepensin also inhibits human CYP1A1, CYP1A2, CYP2A13, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 to different extents .

HY-N0920

Dihydrokavain 7,8-Dihydrokawain; 7,8-Dihydrokavain; Marindinin	Structural Classification Natural Products other families Source classification Plants	COX Cytochrome P450
Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects .

HY-N0043

Ginsenoside Rd 1 Publications Verification Gypenoside VIII	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Endogenous metabolite Disease Research Fields Araliaceae Cancer	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

HY-N0688R

Linderane (Standard)	Structural Classification Terpenoids Sesquiterpenes Source classification Plants Lauraceae Lindera aggregata (Sims) Kosterm.	Reference Standards Cytochrome P450
Linderane (Standard) is the analytical standard of Linderane. This product is intended for research and analytical applications. Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N0920R

Dihydrokavain (Standard) 7,8-Dihydrokawain (Standard); 7,8-Dihydrokavain (Standard); Marindinin (Standard)	Structural Classification Natural Products other families Source classification Plants	Reference Standards COX Cytochrome P450
Dihydrokavain (Standard) (7,8-Dihydrokawain (Standard)) is the analytical standard of Dihydrokavain (HY-N0920). This product is intended for research and analytical applications. Dihydrokavain is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects.

HY-N0043R

Ginsenoside Rd (Standard) Gypenoside VIII (Standard)	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Endogenous metabolite Disease Research Fields Araliaceae Cancer	Reference Standards NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-N1201S1

Apigenin-13C
Apigenin- ¹³C is the ¹³C-abeled Apigenin (HY-N1201). Apigenin is a competitive CYP2C9 inhibitor with a K_i of 2 μM .

HY-N1201S

Apigenin-d5
Apigenin-d5 is a deuterated labeled Apigenin . Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-100386S

Ticlopidine-d4

Ticlopidine-d₄ is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-163816

Antiproliferative agent-53-d3

Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

Cat. No.	Product Name		Classification

HY-114759

MS-PPOH		Alkynes
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and *CYP2C9* with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CYP2C9 inhibitor

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products